(5-bromoisoxazol-3-yl)methanol | 1446408-51-0

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: (5-bromoisoxazol-3-yl)methanol
• 英文别名: 5-Bromo-3-isoxazolemethanol；(5-bromo-1,2-oxazol-3-yl)methanol
• CAS: 1446408-51-0
• 化学式: C₄H₄BrNO₂
• 分子量: 177.985
• InChiKey: MEVWPRDNLPDOEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (5-bromoisoxazol-3-yl)methanol 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以64%的产率得到5-bromoisoxazole-3-carbaldehyde
  参考文献：
  名称：

  Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzuki–Miyaura Cross-Coupling Reaction

  摘要：

  The existence of multidrug-resistant influenza viruses, coupled with the continuously antigenic shift and antigenic drift of influenza viruses, necessitates the development of the next-generation of influenza antivirals. As the AM2-S31N mutant persists in more than 95% of current circulating influenza A viruses, targeting the AM2-S31N proton channel appears to be a logical and valid approach to combating drug resistance. Starting from compound 1, an isoxazole compound with potent AM2-S31N channel blockage and antiviral activity, in this study we report an expeditious synthetic strategy that allows us to promptly explore the structure activity relationships of isoxazole-containing AM2-S31N inhibitors. Propelled by the convenient synthesis, the lead optimization effort yielded a number of potent antivirals with submicromolar efficacy against several human clinical isolates of influenza A viruses, including both oseltamivir-sensitive and -resistant strains.

  DOI：

  10.1021/acs.jmedchem.6b01852
• 作为产物：
  描述：

  ethyl 5-bromoisoxazole-3-carboxylate 在 二异丁基氢化铝 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 生成 (5-bromoisoxazol-3-yl)methanol
  参考文献：
  名称：

  [EN] IL4I1 INHIBITORS AND METHODS OF USE
  [FR] INHIBITEURS D'IL4I1 ET PROCÉDÉS D'UTILISATION

  摘要：

  以下是公式（I）的化合物或其药学上可接受的盐，其中R1、R2、R3、R4、R5、L、X和Y的定义如下。公式（I）的化合物作为IL4I1抑制剂，可用于预防、治疗或作为治疗IL4I1相关疾病的治疗剂。本文还提供了包含本发明化合物或其药学上可接受的盐及药学上可接受的载体的制药组合物，以及使用本发明化合物进行治疗的方法。

  公开号：

  WO2022232333A1

文献信息

• INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF
  申请人：[en]MAZE THERAPEUTICS, INC.

  公开号：WO2024112831A1

  公开（公告）日：2024-05-30

  Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R1, R2, R3, R4, R5, R8, X and Y are as defined elsewhere herein. Also provided herein are methods of preparing compounds of formula (I). Also provided herein are methods of inhibiting SLC6A19 and methods of treating a SLC6A19-mediated disease, disorder, or condition in an individual in need thereof.